Presenter: David Rimm, M.D., Ph.D. | Professor of Pathology and of Medicine (Medical Oncology), Director of Pathology Tissue Services, Yale University School of Medicine
Surprisingly, there are currently no quantitative tests in practice in routine anatomic pathology. This may be due to the unanticipated challenges of reproducible quantification, or the political or financial issues related to the role of pathologists in health care. This presentation will discuss these issues and provide potential solutions to continuous measurement and standardization in anatomic pathology in preparation for new drugs, that will require more than binary information to select the right patient for the right drugs.
During this webinar, the presenter will discuss:
Dr. David Rimm is a Professor in the Departments of Pathology and Medicine (Medical Oncology) at the Yale University School of Medicine. He is also the Director of Yale Pathology Tissue Services and completed an M.D.-Ph.D. at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. Dr. Rimm is boarded in anatomic and cytopatholgy. Dr. Rimm's research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab and other quantitative methods, with projects related to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs. Dr. Rimm's lab is involved in testing new high-plex methods including imaging mass cytometry (Fluidigm) and digital spatial profiling (NanoString). He has supported projects related to rapid, low-cost diagnostic tests. The work is supported by grants from the NIH, BCRF and backed research agreements from biopharma. Dr. Rimm serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. Dr. Rimm is an author of over 400 peer-reviewed papers and eight patents.